ArticleDiabetes therapy : research, treatment and education of diabetes and related disorders2023
Gaps Remain for Achieving HbA1c Targets for People with Type 1 or Type 2 Diabetes Using Insulin: Results from NHANES 2009-2020.
Article in Diabetes therapy : research, treatment and education of diabetes and related disorders, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 41 citations in OpenAlex.
- Efficacy and safety of once-weekly basal insulin therapy in people with type 1 diabetes: A systematic review and meta-analysis.Diabetes, obesity & metabolism · 2026Pooled it
- Hemoglobin A1c association patterns with cardiovascular outcomes among patients with diabetes mellitus following percutaneous coronary intervention: A systematic review.Diabetes & vascular disease researchPooled it
- Rapid improvements in glycemic management with use of continuous glucose monitoring in adults with type 2 diabetes treated with basal insulin: 3-month analysis of the MOBILE study.BMJ open diabetes research & care · 2025Trial
- De-intensification of basal-bolus therapy by replacing prandial insulin with once-weekly subcutaneous semaglutide in individuals with well-controlled type 2 diabetes: A single-centre, open-label randomised trial (TRANSITION-T2D).Diabetes, obesity & metabolism · 2025 · on this mapTrial
- Trial
- Effectiveness and Safety of Semaglutide in Type 1 Diabetes: A Danish Nationwide Cohort Study (2018-2024).The Lancet regional health. Europe · 2026Article
- Article
- Machine Learning Framework for HbA1c Prediction: Data Enrichment, Cost Optimization, and Interpretability Through Stratified Regression and Multi-Stage Feature Selection.Diagnostics (Basel, Switzerland) · 2026Article
- Ability of the DHAM Score to Predict 5-Year All-Cause Mortality in Patients With Diabetes and Comorbid Hypertension: Validation and Risk Stratification in Two Prospective Cohorts.Journal of diabetes research · 2026Article
- Retrospective analysis of impact of automated insulin delivery technology on acute care utilisation from 2019 to 2021.Diabetic medicine : a journal of the British Diabetic Association · 2025Observational
- The impact of monetary incentives and gamification on glucose levels: real-world assessment in people with diabetes.Scientific reports · 2025Article
- Improvements in Glycemic Control With a Digital Diabetes Logbook: Secondary Analysis of a Randomized Controlled Trial Enriched by Observational, Real-World Data.Journal of medical Internet research · 2025Observational
- Article
- The role of advanced technologies in improving diabetes outcomes.The American journal of managed care · 2025Review
- Improved glycemic outcomes in people with type 2 diabetes using smart blood glucose monitoring integrated with popular digital health therapeutics.Scientific reports · 2025Article
- From Microbes to Metabolites: Advances in Gut Microbiome Research in Type 1 Diabetes.Metabolites · 2025Review
- Automating Insulin Dosing and Delivery: The Latest in Algorithms, Calculators, and Devices.Diabetes spectrum : a publication of the American Diabetes Association · 2025Article
- Assessing the iLet Bionic Pancreas Deployed in Primary Care and via Telehealth: A Randomized Clinical Trial.Clinical diabetes : a publication of the American Diabetes Association · 2025Article
- Connected Insulin Pens and Pen Caps: Expanding Diabetes Technology Access and Adoption.Diabetes spectrum : a publication of the American Diabetes Association · 2025Article
- The genetic and observational nexus between diabetes and arthritis: a national health survey and mendelian randomization analysis.Nutrition & diabetes · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionGlycated hemoglobin A1c (HbA1c) is an important measure to assess glycemic control and predict diabetes complications. However, there is limited information on trends in HbA1c among people with diabetes (PwDs) who use insulin. The aim of this study was to describe trends in HbA1c among PwDs who use insulin by diabetes type and insulin regimen.
methodsA retrospective analysis was conducted using data from the National Health and Nutrition Examination Survey (NHANES, 2009-2020). PwDs were classified into three cohorts: type 1 diabetes mellitus (T1DM), type 2 diabetes mellitus using mealtime insulin (T2DM-MTI), and type 2 diabetes mellitus (T2DM) using basal-only insulin (T2DM basal-only). Trends in HbA1c over time were assessed using regression analysis after adjusting for age, gender, and race/ethnicity.
resultsMean HbA1c values aggregated over 2009-2020 were 8.0% (T1DM), 8.6% (T2DM-MTI), and 8.6% (T2DM basal-only). The American Diabetes Association-recommended target of HbA1c of < 7% was achieved by 25.2% of people in the T1DM and T2DM-MTI groups each and by 12.3% of people in the T2DM basal-only group. Over time, an upward trend was observed in the percentage of people achieving HbA1c < 7% in the T2DM basal-only group. The percentage of PwDs achieving individualized HbA1c targets was 27.0%, 12.4%, and 16.1% for the T1DM, T2DM-MTI, and T2DM basal-only groups, respectively.
conclusionsOur study using NHANES data suggests that approximately 25% of PwDs achieve glycemic targets. This study highlights the need for improved therapies to better manage glycemic targets in PwDs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.